26 results about "Uridine diphosphate" patented technology

The invention discloses a preparation method of glucosyl stevioside, and relates to the technical field of glucosyl stevioside production, rebaudioside A or stevioside is taken as a raw material, cyclodextrin is taken as an auxiliary material, cyclodextrin glucosyltransferase is added for glycosylation reaction, a glucosyl stevioside solution I is cooled, and a glucosyl stevioside solution II is obtained; the method comprises the following steps: adding sucrose, UGT glycosyl transferase, sucrose synthase and uridine diphosphate into rebaudioside A or stevioside, continuously converting unreacted rebaudioside A or stevioside into rebaudioside D or rebaudioside E, inactivating after the reaction is finished, filtering by a plate frame, removing impurities through resin, analyzing the resin by using ethanol to obtain an analysis solution, and treating the analysis solution at 78-82 DEG C for 2-4 hours to obtain the rebaudioside D or rebaudioside E; and dealcoholizing at the vacuum degree of-0.1 MPa, concentrating and drying to obtain the glucosyl stevioside. The quality of the product is improved, the cost is reduced, and the taste of the product is integrally improved.

The utility model discloses a preparation device of glucose stevioside, and relates to the technical field of glucose stevioside production, an inlet of a conversion tank is respectively communicated with a raw material tank, an auxiliary material tank and a cyclodextrin glucoside transferase tank, an outlet of the conversion tank is communicated with a hydrolysis tank, an outlet of the hydrolysis tank is communicated with a reaction tank, and the reaction tank is communicated with a reaction tank. The inlet of the reaction tank is respectively communicated with a sucrose tank, a sucrose synthase tank, a uridine diphosphate tank, a first UGT glycosyltransferase tank, a second UGT glycosyltransferase tank and an alkali liquor tank; an outlet of the reaction tank is communicated with a first macroporous adsorption resin column, an inlet of the first macroporous adsorption resin column is communicated with a first ethanol tank, an outlet of the first macroporous adsorption resin column is communicated with a first concentration tank, and a lower outlet of the first concentration tank is communicated with a first dryer; and an outlet of the first dryer is communicated with a first glucosyl stevioside tank. And the residual substrate is converted into stevioside with relatively better taste, so that the taste and quality of the product are improved.

The application discloses a kind of compositions for inhibiting uridine diphosphate glucuronosyltransferase 1A9 activity and application thereof, belong to medical technology field.The composition includes two kinds or more in alpha-antiarol, beta-antiarol, gamma-antiarol, garcinia C, garcinia D, 8-deoxy-garcinol, garcinol and 3-isoantiarol.The application verifies by experiment that the extract of fruit mountain bamboo has higher affinity and stronger inhibitory activity to UGT1A9 in alpha-antiarol, beta-antiarol, gamma-antiarol, garcinia C, garcinia D, 8-deoxy-garcinol, garcinol and 3-isoantiarol, and the components have higher biological activity and safety, can be used as the selective inhibitor of UGT1A9, to inhibit the metabolism of clinical immunosuppressive drug mycophenolic acid, increase mycophenolic acid exposure, prolong the half-life of mycophenolic acid, improve mycophenolic acid efficacy.

The utility model discloses a kind of multi-enzyme step-by-step preparation glucosyl steviol glycoside's device, it is related to glucose steviol glycoside production technical field, the inlet of first reaction tank is respectively communicated with raw material tank, dextrin tank, cyclodextrin glucoside transferase tank and first sodium hydroxide solution tank, the outlet of first reaction tank is communicated with hydrolysis tank, the outlet of hydrolysis tank is communicated with second reaction tank, the inlet of second reaction tank is respectively communicated with sucrose tank, sucrose synthase tank, uridine diphosphate tank, UGT glycosyltransferase tank and lye tank, the outlet of second reaction tank is communicated with concentration tank by pipeline, the lower outlet of concentration tank is communicated with drier, the outlet of drier is communicated with glucosyl steviol glycoside tank. Make residual substrate conversion is relatively more optimal steviol glycoside in taste, improve the taste, quality and yield of product.

The invention relates to the technical field of metabonomics analysis, in particular to application of a metabolic marker in preparation of a head and neck squamous cell carcinoma diagnostic product, a kit, a screening method of the metabolic marker of the head and neck squamous cell carcinoma, a diagnostic model and a construction method and application of the diagnostic model. The metabolic marker comprises at least one of lactic acid, sphingosine, cadaverine, uridine diphosphate, allantoic acid, hydroxyproline, sphingosine-1-phosphoric acid, indole-3-acetaldehyde, pantothenic acid, fumaric acid, malic acid, prostaglandin or ornithine in red blood cells and / or plasma. The screened red blood cells and plasma metabolism markers can be used for predicting or diagnosing the head and neck squamous cell carcinoma respectively or independently, particularly, the red blood cell metabolism markers can provide more stable tumor microenvironment information, and the metabolism stability is high and is not easily influenced by diet and circadian rhythm.

The mutant sucrose synthase satisfies the following (1) and / or (2) and has an amino acid sequence having 70% or more identity to the amino acid sequence of SEQ ID NO: 1. (1) An amino acid residue corresponding to the 348th position from the N-terminus in the amino acid sequence of SEQ ID NO: 1 is substituted with an amino acid other than said amino acid residue and having improved enzyme activity compared to before substitution. (2) An amino acid residue corresponding to the 618th position from the N-terminus in the amino acid sequence of SEQ ID NO: 1 is substituted with an amino acid other than said amino acid residue and having improved enzyme activity compared to before substitution.

The present application relates to methods for preparing rebaudioside D and rebaudioside M by reaction of uridine diphosphate (UDP)-glycosyltransferases; and compositions for preparing rebaudioside D and rebaudioside M, comprising uridine diphosphate (UDP)-glycosyltransferases.

The invention discloses a recombinant Pasteurella multocida-sourced uridine diphosphate glucuronide transferase (PmHS2) mutant and a preparation method thereof, and relates to the technical field of biology, the mutant is obtained by cloning a coding gene to a pET26b (+) vector, transforming BL21 (DE3) Escherichia coli competent cells, and then transforming the recombinant Pasteurella multocida-sourced uridine diphosphate glucuronide transferase (PmHS2) to a pET26b (+) vector. And carrying out IPTG (isopropyl-beta-d-thiogalactoside) induced culture, ultrasonication and nickel affinity chromatography purification to obtain high-purity protein. Compared with wild type recombinant PmHS2, the activity of N-acetyl glucosamino transferase of the mutant is improved by 70%, the residual activity is 67.1% after the mutant is stored at room temperature for 5 days, the soluble expression quantity is improved by 6 times, and the mutant and the preparation method have the advantages of high catalytic efficiency, high stability and high solubility, and the mutant and the preparation method are mature in process, controllable in cost and suitable for industrial production. The method can be efficiently used in the fields of heparin and derivative synthesis, traditional Chinese medicine active ingredient glycosylation and the like, is suitable for large-scale production and has a wide application prospect.

The invention relates to a uridine diphosphate-glucuronyl transferase mutant and an application of the uridine diphosphate-glucuronyl transferase mutant in catalytic synthesis of glucuronide. The amino acid sequence of the uridine diphosphate-glucuronyl transferase mutant is as shown in SEQ ID NO. 2, and the nucleotide sequence of the coding gene is as shown in SEQ ID NO. 1. The invention provides a uridine diphosphate-glucuronyl transferase mutant with high activity and high stability. Compared with wild uridine diphosphate-glucuronyl transferase, the uridine diphosphate-glucuronyl transferase mutant has mutation of 10 amino acid sites. According to experimental determination, the melting temperature of the mutant is increased by 24 DEG C compared with that of a wild type, the activity is increased to 1.65 times, the expression quantity is increased to 4.2 times, and a powerful tool is provided for enzymatic synthesis of glucuronide compounds.

The invention disclosed herein relates generally to the field of recombinant production of a steviol glycoside, to the field of bioconversion of steviol into a steviol glycoside and to the field of bioconversion of a steviol glycoside into a further steviol glycoside. Particularly, the invention provides a process for recombinant production of a steviol glycoside, a process of bioconversion of steviol into a steviol glycoside, a process for bioconversion of a steviol glycoside into a further steviol glycoside and a composition comprising a steviol glycoside. More particularly, the invention relates to a microorganism that has a deficiency of a serine / threonine protein kinase and comprises a polynucleotide encoding a polypeptide having uridine diphosphate-dependent glucosyltransferase (UGT) activity.

The utility model discloses a glucosyl stevioside production device, and relates to the technical field of glucosyl stevioside production, an inlet of a conversion tank is communicated with a raw material tank, a cyclodextrin tank, a beta cyclodextrin transferase tank and a first alkali liquor tank, and an outlet of the conversion tank is communicated with a reaction tank; an inlet of the reaction tank is respectively communicated with a sucrose tank, a sucrose synthase tank, a uridine diphosphate tank, a UGT glycosyltransferase tank and a second alkali liquor tank through pipelines, an outlet of the reaction tank is communicated with a cation exchange resin column, an inlet of the cation exchange resin column is communicated with an ethanol tank, an outlet of the cation exchange resin column is communicated with a concentration tank, and the concentration tank is communicated with a second alkali liquor tank. An outlet of the concentration tank is communicated with a dryer, and an outlet of the dryer is communicated with a glucosyl stevioside tank. The residue of unreacted glucoside in the glucosyl stevioside is reduced through a double-enzyme method, the conversion rate of a substrate is improved, the residue of the substrate is further reduced, and the taste of the product is integrally improved.

Provided is an intestinal bacterium for protecting intestinal barrier function by including Bifidobacterium adolescentis as an active ingredient, which exhibits higher efficacy than conventional strains, wherein as an active component of the intestinal barrier protective agent, there is a cell wall polysaccharide fraction and / or cytoplasmic fraction of Bifidobacterium adolescentis, comprising a polysaccharide having a repeating structure of rhamnose, glucose, and galactose at a ratio of 4-3:1:2-1, fractionated using an ultrafiltration membrane to obtain molecules with a molecular weight of 10,000-30,000, or uridine diphosphate-N-acetylmuramic acid-L-alanine-D-glutamic acid-L-lysine.

The invention relates to uridine diphosphate-N-difluoroacetyl galactosamine as well as a preparation method and application thereof. The chemical structure of the UDP-GalNDFA is similar to that of a natural substrate UDP-GalNAc, and the core difference is that N-acetyl at the site 2 of the UDP-GalNDFA is replaced by N-difluoroacetyl. The preparation method comprises the following steps: (1) preparing difluoroacetyl galactosamine; and (2) preparing the UDP-GalNDFA by taking the difluoroacetyl galactosamine as a substrate. As a novel artificial donor sugar, the UDP-GalNDFA has the characteristics of high activity, difficulty in hydrolysis and capability of being artificially synthesized. Compared with the existing donor sugar UDP-GalNTFA, the glucose UDP-GalNTFA has higher catalytic activity on glycosyl transferase, has stronger stability, is not easy to hydrolyze, and can be used as a donor substrate for synthesizing a chondroitin oligosaccharide skeleton, a chondroitin oligosaccharide intermediate and a chondroitin oligosaccharide derivative by a chemical enzyme method.

This invention relates to the field of fermentation engineering technology, and particularly to a mutant of uridine 5′-bisphosphate-N-acetylglucosamine 2 epimerase and its application. The mutant is based on the amino acid sequence of uridine 5′-bisphosphate-N-acetylglucosamine 2 epimerase, including any one of the following: i) a mutation of S263Q or S263L; ii) in addition to i), a mutation of one of F266W, F266Y, F266I, or F266L. This invention has discovered multiple mutation modes of uridine 5′-bisphosphate-N-acetylglucosamine 2 epimerase, and its application in the construction of sialyl lactose-producing *Escherichia coli* can effectively increase the yield of sialyl lactose, which has significant application value in the field of sialyl lactose production.

The application provides a chondroitin synthase mutant and application thereof, and relates to the technical field of biology.The chondroitin synthase mutant is obtained by firstly performing deletion on N-terminal and C-terminal amino acid sequences of chondroitin synthase with an amino acid sequence as shown in SEQ ID NO.1 and performing compound mutation on amino acids at positions 200, 279 and 346, introducing the chondroitin synthase mutant into a plasmid to form a recombinant plasmid, introducing the recombinant plasmid into a recombinant bacterium for fermentation culture, and finding that the chondroitin synthase mutant can significantly improve the yield of chondroitin.In addition, the application also overexpresses N-acetylglucosamine epimerase, 6-phosphoglucosamine synthetase, 6-phosphoglucosamine synthetase and uridine diphosphate-glucose dehydrogenase, and constructs the overexpressed enzymes into a protein polymer through CipA protein, so that the synthesis efficiency of chondroitin is improved, and the yield of chondroitin obtained through fermentation in a 5L fermentation tank is about 10.5g / L.

The application relates to the technical field of medicines, in particular to a kind of nanometer material for delivering UDP-GlcNAc and its preparation method and application.The application provides a kind of nanometer material for delivering UDP-GlcNAc, the nanometer material is prepared by co-precipitation method from metal ion and uridine diphosphate-N-acetylglucosamine;Wherein, the metal ion includes magnesium ion, calcium ion, iron ion, zinc ion, aluminum ion, copper ion, manganese ion, cobalt ion, nickel ion and chromium ion in any one of them.The efficient intracellular delivery is realized, and the drug action time is prolonged, which is beneficial to wide application.

The present invention belongs to the technical field of biology and relates to a recombinant Escherichia coli for producing lacto-N-triose and a two-strain-coupled fermentation method based on same. The provided recombinant Escherichia coli for producing lacto-N-triose expresses three genes N-acetylhexosamine 1-kinase gene Nahk, uridine diphosphate-N-Acetylglucosamine pyrophosphorylase gene GlmU, and β-1,3-N-acetylglucosaminyltransferase gene LgtA. The coupled catalysis of the obtained recombinant Escherichia coli and yeast to produce lacto-N-triose is a two-stage fermentation process, wherein the first stage is to culture engineered Escherichia coli, and the second stage is to perform coupled fermentation by means of the yeast and the recombinant Escherichia coli, the yield on a 5L fermentation tank being 52.2 g / L. The provided fermentation production process is simple and has a high conversion rate, and thus has good industrialization prospects.

The invention discloses a method for multi-enzyme step-by-step preparation of glucosyl stevioside, and relates to the technical field of glucosyl stevioside preparation.The method comprises the steps that crushed rebaudioside A serves as a raw material, dextrin serves as an auxiliary material, cyclodextrin glucoside transferase is added for a glycosylation reaction, a glucosyl stevioside solution I is cooled, and a glucosyl stevioside solution II is obtained; the method comprises the following steps of: adding a saccharifying enzyme to hydrolyze, adding cane sugar, UGT glycosyl transferase, cane sugar synthase and uridine diphosphate, continuously converting unreacted rebaudioside A into stevioside RI, inactivating after the reaction, adsorbing with resin, desorbing with ethanol, dealcoholizing a desorbed solution, concentrating and drying to obtain the glucosyl stevioside. The quality of the product is improved, the cost is reduced, and the taste of the product is integrally improved.

The application provides a 3'-O-beta-glucosyl-ribavirin compound and a preparation method and application thereof, and the method comprises the following steps: taking uridine diphosphate-glucose and ribavirin as raw materials, and synthesizing the 3'-O-beta-glucosyl-ribavirin compound under the catalysis of a glycosyltransferase, the reaction condition is mild, the operation is simple, the yield is high, and the method is suitable for industrial production. The 3'-O-beta-glucosyl-ribavirin compound prepared by the application has obvious inhibitory effect on influenza virus and enterovirus, and the antiviral effect is higher than that of the present clinical drug ribavirin, and the 3'-O-beta-glucosyl-ribavirin compound can be used as an antiviral drug candidate.

The invention belongs to the technical field of biological medicines, and particularly relates to uridine-5 '-diphosphate polydeoxy diamino sugar as well as a preparation method and application thereof. According to the invention, uridine-5 '-diphosphate-N-acetyl-glucosamine is used as a substrate to prepare UDP-kasuramine and a new structural analogue UDP-3 ''-hydroxyl-kasuramine of the UDP-kasuramine. The compound can be used as a medical intermediate for preparing commercial agricultural and medical antibiotic kasugamycin and derivatives thereof without / with low toxic and side effects. The method is simple and convenient to operate, mild in condition, environment-friendly and relatively high in conversion rate, and has a good application prospect.

The invention disclosed herein relates generally to the field of recombinant production of a steviol glycoside, to the field of bioconversion of steviol into a steviol glycoside and to the field of bioconversion of a steviol glycoside into a further steviol glycoside. Particularly, the invention provides a process for recombinant production of a steviol glycoside, a process of bioconversion of steviol into a steviol glycoside, a process for bioconversion of a steviol glycoside into a further steviol glycoside and a composition comprising a steviol glycoside. More particularly, the invention relates to a microorganism that has a deficiency of a serine / threonine protein kinase and comprises a polynucleotide encoding a polypeptide having uridine diphosphate-dependent glucosyltransferase (UGT) activity.

The present invention provides polynucleotide sequences derived from Helichrysum umbraculigerum and encoding a protein or a plurality thereof belonging to the uridine diphosphate (UDP)-glycosyltransferase (UGT) family. Further provided are an artificial nucleic acid molecule including the polynucleotide disclosed herein, a transgenic cell, tissue, or plant including same.

This disclosure relates to mRNA therapy for the treatment of Crigler-Najjar Syndrome Type 1 (CN-1). mRNAs for use in the invention, when administered in vivo, encode uridine diphosphate glycosyltransferase 1 family, polypeptide A1 (UGT1A1). mRNA therapies of the disclosure increase and / or restore deficient levels of UGT1A1 expression and / or activity in subjects. mRNA therapies of the disclosure further decrease abnormal accumulation of bilirubin associated with deficient UGT1A1 activity in subjects.

The invention provides methods for making steviol glycosides, including RebM and glycosylation products that are minor products in stevia leaves, and provides enzymes, encoding polynucleotides, and host cells for use in these methods. The invention provides engineered enzymes and engineered host cells for producing steviol glycosylation products, such as RebM, at high purity and / or yield. The invention further provides methods of making products containing steviol glycosides, such as RebM, including food products, beverages, oral care products, sweeteners, and flavoring products.

This study aims to elucidate the active mechanism responsible for the intestinal barrier protection effect of Bifidobacterium adolescentis. [Solution] An intestinal barrier protectant comprising a polysaccharide having a repeating structure of the cell wall polysaccharide fraction and / or intracytoplasmic fraction of Bifidobacterium adolescentis, rhamnose, glucose, and galactose in a ratio of 4-3:1:2-1, with a fractional molecular weight of 1-30,000 determined by ultrafiltration membrane, or uridine diphosphate-N-acetylmuramic acid-L-alanine-D-glutamic acid-L-lysine as an active ingredient.